Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Daily Summary: A Shallow Rebound Ahead of Earnings Season
Lumentum: Demand for AI infrastructure exceeds capacity
US OPEN: Trump de-escalates, OpenAI supports Wall Street sentiment
Morning Wrap: OpenAI Revenue Concerns Weigh on Wall Street